Biofrontera Inc. to Report Third Quarter Financial Results on November 14, 2022

Rhea-AI Summary

Biofrontera Inc. (Nasdaq: BFRI) will release its financial results for the three and nine months ending September 30, 2022, on November 14, 2022, prior to the U.S. market opening. A conference call is scheduled for the same day at 11:00 a.m. Eastern time to discuss these results and provide a business update. The call can be accessed via phone or a webcast, which will also be available for replay for 90 days. Biofrontera specializes in dermatological pharmaceuticals, notably in treating actinic keratoses and bacterial skin infections.

Positive

• Scheduled conference call for Q3 2022 results demonstrates transparency and commitment to investor communication.

Negative

• No specific financial metrics or guidance disclosed could indicate potential concerns about performance.

WOBURN, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and nine months ended September 30, 2022 before the opening of the U.S. financial markets on Monday, November 14, 2022. The Company will hold a conference call that same day beginning at 11:00 a.m. Eastern time to discuss those results, provide a business update and answer questions.

Conference Call and Webcast Information

Event:	Biofrontera Inc. Third Quarter 2022 Financial Results and Business Update Conference Call
Date:	Monday, November 14, 2022
Time:	11:00 a.m. Eastern time
Conference call:	1-877-877-1275 (U.S.) 1-412-858-5202 (international)
Webcast:	Live and 90-day replay webcast are available here and at www.investors.biofrontera-us.com.

About Biofrontera Inc.

Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company’s licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit www.biofrontera-us.com.

Contacts

Biofrontera Inc.
Anke zur Mühlen
+1 781 486 1539
us-ir@biofrontera.com

LHA Investor Relations
Tirth T. Patel
+1 212 201 6614
tpatel@lhai.com

#    #    #

FAQ

When will Biofrontera report its financial results for Q3 2022?

Biofrontera will report its Q3 2022 financial results on November 14, 2022.

What time is the Biofrontera conference call to discuss financial results?

The conference call is scheduled for 11:00 a.m. Eastern time on November 14, 2022.

How can I access the Biofrontera financial results conference call?

You can access the call via phone or through a webcast available on Biofrontera's investor relations website.

What is the stock symbol for Biofrontera?

The stock symbol for Biofrontera is BFRI for common shares and BFRIW for warrants.